
NANOCARRIER SYSTEMS FOR TRANSDERMAL DRUG DELIVERY

Rushikesh. B. Tembare*¹, Ms. M.R. Deokar*²

*¹Student, Late Laxmibai Phadtare College Of Pharmacy, Kalamb, India.

*²Assistant Professor, Late Laxmibai Phadtare College Of Pharmacy, Kalamb, India.

ABSTRACT

Transdermal drug delivery (TDD) offers a non-invasive alternative to traditional routes of administration, allowing for controlled release of therapeutic agents while bypassing the first-pass metabolism. However, the stratum corneum, the outermost layer of the skin, presents a formidable barrier to drug permeation. Nanocarrier systems have emerged as promising solutions to enhance the transdermal delivery of drugs, providing controlled release, improved stability, and targeted delivery to systemic circulation. This abstract reviews various nanocarrier systems developed for TDD, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, and microneedle systems.

Liposomes are among the earliest nanocarrier systems explored for transdermal applications. Composed of phospholipid bilayers, liposomes can encapsulate both hydrophilic and hydrophobic drugs, enhancing their permeability through the skin. Research has demonstrated that liposome formulations, such as those containing encapsulated diclofenac, improve skin penetration and therapeutic efficacy compared to conventional formulations (Kumar et al., 2021).

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent advancements in lipid-based delivery systems. SLNs combine the benefits of solid lipid matrices with the ability to encapsulate lipophilic drugs, enhancing stability and reducing drug leakage. NLCs, an evolution of SLNs, incorporate both solid and liquid lipids, allowing for a higher drug loading capacity and improved release profiles. Studies have shown that NLCs can enhance the permeation of drugs like ketoprofen through the skin, demonstrating their potential in TDD (Fang et al., 2020).

Polymeric nanoparticles have gained attention for their ability to provide sustained release and controlled drug delivery. Biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), can be tailored to achieve desired release kinetics. Research indicates that polymeric nanoparticles loaded with therapeutic agents, such as anti-inflammatory drugs, exhibit improved skin permeation and enhanced therapeutic outcomes in animal models (Bhatia et al., 2022).

Microneedle systems represent a novel approach in transdermal drug delivery, allowing for the bypassing of the stratum corneum through minimally invasive techniques. These small, micron-sized needles create microchannels in the skin, facilitating the transport of drugs into the systemic circulation. Microneedle patches can be loaded with various formulations, including vaccines and small molecules, and have demonstrated effective delivery in both preclinical and clinical settings (Liu et al., 2021). In summary, nanocarrier systems for transdermal drug delivery offer significant advantages, research focuses on optimizing these systems to further enhance their performance, biocompatibility, and safety profiles. The integration of nanotechnology in TDD holds the potential to revolutionize therapeutic strategies, providing effective treatment options for a wide range of medical conditions.

Keywords: Skin, Skin Function, Routes Of Drug Penetration, Transdermal Drug Delivery System, Nanocarrier System.

I. INTRODUCTION

Transdermal drug delivery (TDD) offers a non-invasive route for the administration of therapeutic agents, presenting significant advantages over traditional oral and injectable methods. This approach facilitates the controlled release of drugs, provides sustained therapeutic effects, and improves patient compliance by avoiding the gastrointestinal tract and first-pass metabolism. However, the efficacy of TDD is primarily hindered by the stratum corneum, the outermost layer of the skin, which serves as a barrier to the permeation of most drugs due to its lipid-rich structure (Duncan, 2019).

To overcome this barrier, researchers have increasingly turned to nanocarrier systems, which can enhance the delivery of drugs across the skin. These nanocarriers are designed to improve the solubility, stability, and permeation of drugs while allowing for controlled release and targeted delivery. Various types of nanocarriers, including liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, and microneedle systems, have shown promise in enhancing transdermal delivery (Patel et al., 2020; Jain et al., 2021).

Liposomes, first introduced in the 1960s, are spherical vesicles composed of phospholipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs (Barenholz, 2012). Their ability to improve the skin permeability of drugs has led to their application in TDD, providing advantages such as enhanced stability and reduced side effects. Recent studies have demonstrated the effectiveness of liposome formulations in delivering anti-inflammatory drugs through the skin, indicating their potential for transdermal applications (Kumar et al., 2021).


Solid lipid nanoparticles (SLNs) are another significant advancement in nanocarrier technology. These nanoparticles consist of solid lipids that encapsulate the drug, offering controlled release properties and improved stability compared to traditional formulations (Fang et al., 2020). SLNs have been explored for the transdermal delivery of various drugs, demonstrating enhanced skin permeation and therapeutic efficacy (Sharma et al., 2021).

An evolution of SLNs, nanostructured lipid carriers (NLCs) combine solid and liquid lipids to improve drug loading capacity and control release profiles. NLCs have garnered attention for their potential to enhance transdermal drug delivery by increasing skin permeability and prolonging the release of the active pharmaceutical ingredient (Chakraborty et al., 2019).

Polymeric nanoparticles are also widely investigated for their use in TDD. These biodegradable carriers can be designed to achieve specific release kinetics, allowing for tailored drug delivery (Bhatia et al., 2022). Research has shown that polymeric nanoparticles loaded with anti-inflammatory drugs can improve skin permeation and therapeutic outcomes in preclinical studies (Tiwari et al., 2020).

Microneedle systems represent a novel approach that involves the use of minimally invasive techniques to create microchannels in the skin, facilitating drug delivery to the systemic circulation. This innovative method enables the bypassing of the stratum corneum and enhances drug absorption (Liu et al., 2021). Microneedle patches have been developed for various applications, including vaccines and small molecules, demonstrating their effectiveness in clinical settings (Gao et al., 2023).

In conclusion, nanocarrier systems for transdermal drug delivery offer exciting possibilities for enhancing drug permeation, improving therapeutic efficacy, and providing controlled release of medications. Ongoing research in this field aims to optimize these systems for better performance, safety, and biocompatibility, paving the way for their clinical applications in modern therapeutics.



II. STRUCTURE AND FUNCTION OF THE SKIN

The skin is the largest organ of the human body, playing a vital role in protecting underlying tissues from external insults while also regulating physiological processes. Understanding the structure and function of the skin is essential for comprehending its role in health and disease, as well as its interaction with various therapeutic agents, including those delivered via transdermal routes.

1. Structure of the Skin

The skin is composed of three primary layers: the epidermis, dermis, and hypodermis (or subcutaneous layer).

1.1 Epidermis

The epidermis is the outermost layer of the skin, consisting primarily of keratinocytes, which are responsible for the production of keratin, a protein that provides strength and waterproofing. The epidermis is further divided into several sub-layers:

Stratum Corneum : The outermost layer composed of dead, flattened keratinized cells that form a protective barrier against environmental threats and prevent water loss.

Stratum Lucidum : Present only in thick skin (e.g., palms and soles), this thin layer provides an additional barrier.

Stratum Granulosum : This layer contains keratinocytes that begin to lose their nuclei and accumulate keratohyalin granules, contributing to keratin formation.

Stratum Spinosum : Composed of several layers of keratinocytes connected by desmosomes, this layer provides strength and flexibility to the skin.

Stratum Basale : The deepest layer of the epidermis, consisting of a single row of actively dividing cells (stem cells) that continuously produce new keratinocytes.

The epidermis also contains melanocytes, which produce melanin and contribute to skin pigmentation, as well as Langerhans cells, which play a role in immune defense (Madison, 2003).

1.2 Dermis


The dermis lies beneath the epidermis and is significantly thicker. It is primarily composed of connective tissue, providing strength and elasticity to the skin. The dermis is divided into two layers:

Papillary Dermis : The upper layer characterized by thin collagen fiber and dermal papillae that interdigitate with the epidermis. This layer contains capillaries, lymphatics, and sensory neurons, providing nourishment and sensation to the epidermis.

Reticular Dermis : The thicker, lower layer composed of dense irregular connective tissue, containing larger collagen and elastin fibers. This layer houses sweat glands, sebaceous glands, hair follicles, and larger blood vessels (Kumar et al., 2022).

1.3 Hypodermis (Subcutaneous Layer)

The hypodermis, or subcutaneous tissue, is the deepest layer of the skin, composed primarily of adipose tissue and loose connective tissue. It provides insulation, energy storage, and cushioning for underlying structures, such as muscles and bones. The hypodermis also contains larger blood vessels and nerves that extend into the dermis (Rittie & Fisher, 2002).



2. Functions of the Skin

The skin serves multiple critical functions, including:

2.1 Barrier Protection

The skin acts as a physical barrier protecting the body from mechanical injury, pathogens, and harmful substances. The stratum corneum, with its keratinized cells and lipid matrix, plays a crucial role in preventing water loss and minimizing transepidermal water loss (TEWL) (Proksch et al., 2008).

2.2 Thermoregulation

The skin helps regulate body temperature through vasodilation and vasoconstriction of blood vessels in the dermis, as well as through sweat production. When the body temperature rises, sweat glands produce sweat, which evaporates to cool the skin surface (Boulant, 2000).

2.3 Sensation

The skin is rich in sensory receptors that detect changes in the external environment, including temperature, pressure, and pain. These receptors, located in the dermis and epidermis, relay sensory information to the central nervous system (Bresalier et al., 2003).

2.4 Metabolism

The skin plays a role in metabolic processes, such as the synthesis of vitamin D when exposed to sunlight. Vitamin D is essential for calcium homeostasis and bone health (Holick, 2004).

2.5 Immune Defense

The skin serves as a first line of defense against pathogens and foreign substances. Langerhans cells in the epidermis act as antigen-presenting cells, initiating immune responses, while the presence of antimicrobial peptides further enhances the skin's innate immunity (Gallo et al., 2002).

III. ROUTES OF DRUG PENETRATION THROUGH THE SKIN

Transdermal drug delivery is a highly desirable method for administering therapeutic agents due to its non-invasive nature and ability to achieve systemic effects while bypassing first-pass metabolism. The skin provides several potential routes for drug penetration, each with distinct mechanisms and implications for drug design and formulation. Understanding these routes is crucial for optimizing transdermal delivery systems.

1. Intercellular Route

The intercellular route, or paracellular pathway, involves drug permeation between the keratinocytes, the primary cell type in the epidermis. This route is facilitated by the lipid matrix that forms the barrier of the stratum corneum, composed of ceramides, cholesterol, and fatty acids. The intercellular lipid matrix is crucial for maintaining skin barrier function and influences drug permeation.

Drugs that possess moderate lipophilicity can diffuse through these lipid domains, exploiting the lipid bilayer arrangement. This route is particularly effective for small, uncharged molecules, allowing them to traverse the stratum corneum and penetrate deeper layers of the skin (Zhou et al., 2021).

2. Transcellular Route

The transcellular route involves direct penetration through the keratinocytes. Drugs must cross the lipid bilayers and cellular cytoplasm of the keratinocytes. This route is often favored for drugs with suitable size and lipophilicity, as it allows for greater interaction with cellular membranes.

The transcellular pathway is significant for larger molecules and those with specific structural characteristics that enhance their ability to traverse the cellular membranes (Choi et al., 2021). However, this route may be less favorable for highly hydrophilic compounds, which encounter difficulties in crossing lipid membranes.

3. Appendageal Route

The appendageal route includes penetration through hair follicles, sweat glands, and sebaceous glands. Hair follicles represent a less significant route for systemic drug absorption; however, they provide an alternative pathway for drug delivery. The appendageal route can facilitate the permeation of both small and large molecules, as it bypasses the stratum corneum barrier in part (Mitragotri et al., 2019).

This route is particularly relevant for formulations designed to deliver drugs to specific skin structures or for local therapy, such as in the treatment of scalp conditions or acne. Moreover, formulations targeting the

appendageal route may enhance drug delivery efficiency by leveraging the microenvironment within hair follicles (Yin et al., 2016).

4. Microneedle-Assisted Route

Microneedles are minimally invasive devices designed to create microchannels in the skin, allowing drugs to bypass the stratum corneum effectively. These tiny needles penetrate only the upper layers of the skin, providing a painless method for drug delivery while significantly increasing permeation rates for both small and large molecules.

Microneedles can be coated with drugs, or the drugs can be delivered in a liquid formulation. This approach allows for improved bioavailability and reduced side effects compared to conventional transdermal systems (Liu et al., 2021). The microneedle-assisted route offers a promising alternative for the delivery of vaccines and macromolecules (Mok et al., 2019).


5. Chemical Enhancer-Mediated Route

Chemical enhancers, such as surfactants, solvents, or permeation enhancers, can be used to modify the skin barrier properties and facilitate drug penetration. These enhancers alter the lipid structure or fluidity of the stratum corneum, increasing drug permeability.

Common chemical enhancers include ethanol, propylene glycol, and terpenes, which can disrupt the lipid bilayer and create transient defects that allow for enhanced drug passage (Khan et al., 2020). However, the selection of chemical enhancers must be carefully considered, as they can also affect skin integrity and safety.

Skin penetration, also known as percutaneous absorption, refers to the process by which substances pass through the skin layers into the body. It is a critical consideration in dermatology, cosmetics, and pharmaceuticals, especially when formulating topical treatments. Several factors influence the rate and extent of skin penetration, including the physicochemical properties of the penetrant, characteristics of the skin, and external conditions. Below is a detailed examination of these factors:

Skin Penetration Routes



IV. FACTORS AFFECTING SKIN PENETRATION

1. Physicochemical Properties of the Penetrant

a. Molecular Size and Weight

The size of a molecule plays a crucial role in its ability to penetrate the skin. Smaller molecules can more easily pass through the skin layers, whereas larger molecules face greater resistance. Generally, substances with a molecular weight below 500 Daltons are more likely to penetrate the stratum corneum, the outermost layer of the skin.

b. Lipophilicity (Fat Solubility)

The skin's lipid-rich environment, particularly in the stratum corneum, favors the absorption of lipophilic (fat-soluble) compounds. Molecules with higher lipophilicity are able to dissolve more easily in the skin's lipid matrix, enhancing their penetration. However, highly lipophilic compounds may remain trapped in the stratum corneum and not reach deeper layers.

c. Polarity

Non-polar substances generally penetrate the skin more efficiently than polar substances due to the lipophilic nature of the stratum corneum. However, polar substances may still penetrate through other pathways such as appendages (sweat glands, hair follicles), although this is a less dominant route compared to transcellular or intercellular penetration.

d. Ionization State

The ionization of a substance affects its ability to penetrate the skin. Non-ionized molecules penetrate more easily than ionized ones because the latter are less able to diffuse through the lipid-rich environment of the stratum corneum.

2. Skin Condition and Characteristics

a. Skin Thickness

Skin thickness varies depending on the body site and can significantly affect penetration. Areas like the soles of the feet or palms have thicker skin and are more resistant to penetration, whereas thinner areas like the eyelids allow for easier absorption.

b. Hydration Levels

Increased skin hydration generally enhances skin penetration. When the skin is well-hydrated, the stratum corneum swells, creating more space between the corneocytes (skin cells), allowing easier passage of substances. This is the basis for techniques such as occlusion, where a substance is sealed on the skin, increasing hydration and absorption.

c. Skin Age

With aging, the skin undergoes structural changes that may reduce its barrier function, such as thinning of the epidermis and alterations in the lipid composition of the stratum corneum. These changes can either increase or decrease penetration, depending on the nature of the substance .

d. Skin Integrity

Damaged or compromised skin, such as in cases of cuts, abrasions, or conditions like eczema, allows for increased penetration. Disruption of the stratum corneum provides less resistance to external substances, potentially leading to faster and more extensive absorption .

3. Environmental and External Factors

a. Temperature

Higher temperatures increase the kinetic energy of molecules, facilitating faster diffusion through the skin. Warm skin also tends to be more hydrated, further promoting penetration .

b. Occlusion

Occlusion, where the skin is covered (e.g., with a dressing or ointment), prevents water loss from the skin, increasing hydration and softening the stratum corneum. This enhances the penetration of topical formulations, especially those with hydrophilic properties .

c. Application Area

The larger the surface area of the skin exposed to a substance, the more of the substance can be absorbed. This is important in the application of patches or creams, where a broader area can increase systemic absorption .

4. Formulation of the Product

a. Vehicle

The formulation vehicle (e.g., cream, ointment, gel) has a significant impact on the delivery of active ingredients into the skin. Vehicles that increase skin hydration or contain penetration enhancers (e.g., alcohols, surfactants)

can greatly enhance penetration. For example, alcohol can disrupt the lipid barrier, temporarily increasing the permeability of the stratum corneum.

b. Concentration

The concentration of the active ingredient in a formulation affects the driving force for its penetration. Higher concentrations generally result in greater penetration, provided other conditions such as solubility and stability are maintained.

c. pH of the Formulation

The pH of a product can influence the ionization state of the active ingredient, affecting its ability to penetrate the skin. A pH closer to the skin's natural pH (around 4.5 to 6) is generally more favorable for penetration, although some substances require slightly acidic or alkaline conditions to remain non-ionized and permeable .

5. Penetration Enhancers

Various substances, known as penetration enhancers or sorption promoters, are incorporated into formulations to increase skin permeability. They work by interacting with the skin's lipid structure, proteins, or the stratum corneum, often by disrupting the lipid bilayer or altering its organization. Examples of penetration enhancers include alcohols, terpenes, surfactants, and fatty acids .

6. Routes of Penetration

Substances penetrate the skin via three main pathways:

- Transcellular route: Directly through the cells of the epidermis.
- Intercellular route: Between the cells, through the lipid matrix.
- Appendageal route: Via hair follicles, sweat glands, and sebaceous glands, although this is a less significant route.

Transdermal Drug Delivery Systems (TDDS) are a method of delivering medication through the skin, allowing the drug to enter the bloodstream directly. This delivery system is particularly useful for drugs that require steady, controlled release over a prolonged period. While TDDS offers numerous advantages over traditional drug delivery methods, it also comes with several challenges. Below is a detailed discussion of the advantages and disadvantages of TDDS, supported by references.

V. ADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEMS

1. Avoidance of First-Pass Metabolism

One of the major advantages of TDDS is the ability to bypass first-pass metabolism in the liver. When drugs are taken orally, they must first pass through the digestive system and liver, where they can be metabolized and degraded, reducing their efficacy. Transdermal delivery avoids this issue, resulting in improved bioavailability for many drugs. This can be particularly useful for drugs that are extensively metabolized by the liver when administered orally.

2. Controlled and Sustained Drug Release

TDDS allows for the controlled and sustained release of a drug over a specified period, which is beneficial for drugs requiring steady plasma levels. This can minimize the need for frequent dosing, improving patient adherence to the medication regimen. Drugs can be released at a slow, constant rate over several hours or even days, reducing peaks and troughs in drug levels .

3. Improved Patient Compliance

Many patients prefer TDDS because of the convenience and ease of use. Unlike oral medications, which require frequent dosing, or injectable medications, which can be painful, TDDS often involves applying a patch to the skin, making it a non-invasive and less obtrusive option. The ease of use helps improve compliance, particularly for chronic conditions that require long-term medication .

4. Reduction in Gastrointestinal Side Effects

Oral administration of drugs can cause gastrointestinal (GI) side effects, such as nausea, vomiting, or irritation of the stomach lining. TDDS bypasses the GI tract altogether, reducing the incidence of these side effects. This is particularly useful for drugs that are known to cause GI distress .

5. Flexibility in Drug Removal

In the case of adverse reactions or toxicity, TDDS offers the advantage of easy discontinuation by simply removing the patch. Once the patch is removed, drug delivery stops, allowing healthcare providers to intervene before more severe side effects develop .

6. Reduced Frequency of Dosing

Due to the slow and steady release of drugs, TDDS can reduce the frequency of dosing compared to oral or injectable routes. For example, patches that deliver medication over 24 hours or longer are available, reducing the need for multiple daily doses. This enhances convenience and can improve treatment adherence, especially for conditions requiring chronic medication .

7. Potential for Self-Administration

TDDS are often simple to apply, making them suitable for self-administration. Patients can easily apply patches at home without the need for healthcare professionals, which enhances independence and reduces healthcare costs .

VI. DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY SYSTEMS

1. Limited to Drugs with Specific Properties

Not all drugs are suitable for transdermal delivery. Drugs must have appropriate molecular size, lipophilicity, and potency to penetrate the skin and reach therapeutic levels in the bloodstream. Molecules larger than 500 Daltons, for instance, may not effectively penetrate the stratum corneum, limiting the range of drugs that can be delivered via this route .

2. Potential for Skin Irritation and Sensitization

One of the main drawbacks of TDDS is the potential for skin irritation or sensitization at the application site. Prolonged exposure to the adhesive or drug can cause allergic reactions, rashes, or irritation. These reactions can limit patient acceptance and adherence to treatment

3. Variable Skin Permeability

Skin permeability varies significantly depending on factors such as age, hydration, skin thickness, and anatomical site. For instance, the skin on the palms and soles is much thicker and less permeable than the skin on the abdomen or upper arm. This variability can lead to inconsistent drug absorption, affecting the efficacy of the treatment.

4. Limited Dosing Capacity

TDDS is most effective for potent drugs that require only small doses. Because only a limited amount of drug can be delivered through the skin, drugs that require higher doses may not be suitable for transdermal delivery. This limits the range of drugs that can be effectively delivered using this method.

5. Cost and Complex Formulation

The development and production of TDDS can be more expensive compared to traditional dosage forms such as tablets or injections. The cost of creating a patch that provides consistent drug release, adheres to the skin, and maintains stability can be high. Additionally, the process of formulating a drug for transdermal delivery can be complex, involving penetration enhancers and sophisticated release mechanisms.

6. Potential for Drug Loss

Some of the drug in a TDDS can be lost due to poor adhesion of the patch to the skin or detachment during daily activities. Environmental factors like sweating, water exposure, and physical activity can also affect the adhesion and, consequently, the drug delivery. This variability can result in lower-than-expected drug levels in the bloodstream.

7. Allergic Reactions to Adhesives

Many TDDS use adhesives to keep the patch in place, and these adhesives can cause allergic reactions in some individuals. Adhesive-related reactions may present as contact dermatitis, leading to discomfort and limiting the use of the patch.

VII. NANOCARRIER SYSTEMS FOR DRUG DELIVERY



Nanocarrier systems represent a cutting-edge technology for drug delivery, offering a range of benefits such as targeted delivery, controlled release, improved bioavailability, and reduced side effects. Nanocarriers are typically defined as nano-sized structures (ranging from 1 to 1000 nanometers) that can encapsulate, transport, and deliver therapeutic agents to specific tissues or cells in the body. They play a significant role in enhancing the therapeutic efficacy of drugs, especially in cases where conventional drug delivery methods are inadequate. This technology has seen extensive research and development in fields such as oncology, infectious diseases, and gene therapy. Below is an overview of nanocarrier systems and their applications in drug delivery.

• Types of Nanocarrier Systems

1. Liposomes

Liposomes are spherical vesicles with one or more phospholipid bilayers. These structures can encapsulate both hydrophilic and hydrophobic drugs, making them versatile for various therapeutic agents. Liposomes can protect drugs from degradation, enhance bioavailability, and target specific tissues by modifying their surface with ligands (e.g., antibodies or peptides). They are one of the earliest nanocarriers to be approved for clinical use, with several liposomal formulations on the market, such as Doxil (doxorubicin) for cancer therapy .

Advantages:

- Biocompatible and biodegradable
- Ability to carry hydrophilic and hydrophobic drugs
- Low toxicity due to natural phospholipid composition

Disadvantages:

- Limited stability
- Potential for rapid clearance from the bloodstream by the reticuloendothelial system (RES) .

2. Polymeric Nanoparticles

Polymeric nanoparticles are solid colloidal particles composed of biodegradable and biocompatible polymers like poly(lactic-co-glycolic acid) (PLGA) or polyethylene glycol (PEG). Drugs can be encapsulated or conjugated to these nanoparticles, which provide controlled release over time. Polymer-based nanoparticles are versatile and can be tailored for specific drug release profiles, which is especially useful for chronic diseases that require sustained drug release over days or weeks.

Advantages:

- Controlled and sustained drug release
- Versatile in terms of surface modification for targeting

- Stable and easy to manufacture at a large scale

Disadvantages:

- Potential for polymer-related toxicity
- Complex formulation processes .

3. Dendrimers

Dendrimers are highly branched, tree-like macromolecules with a central core. They offer a high degree of functionalization, meaning drugs can be attached to the surface or encapsulated within the dendrimer structure. This high functionality allows for precise drug targeting and delivery. Dendrimers are particularly useful in gene delivery and as carriers for anticancer agents.

Advantages:

- High degree of functionalization for targeted delivery
- Ability to carry multiple drugs simultaneously (combination therapy)
- Suitable for delivering nucleic acids in gene therapy

Disadvantages:

- High cost of production
- Potential toxicity due to residual reactants or unreacted functional groups .

4. Solid Lipid Nanoparticles (SLNs)

SLNs are nanoparticles made from solid lipids. They combine the advantages of polymeric nanoparticles and liposomes, offering good biocompatibility and controlled drug release. SLNs are used to improve the bioavailability of poorly water-soluble drugs, making them a popular choice for oral and transdermal drug delivery. Their solid lipid matrix provides stability and protection for the drug, enhancing its therapeutic effect .

Advantages:

- Good biocompatibility and biodegradability
- Enhanced stability compared to liposomes
- Suitable for a wide range of drug delivery routes (oral, topical, injectable)

Disadvantages:

- Limited drug loading capacity due to the solid lipid matrix
- Potential for drug expulsion during storage .

5. Carbon Nanotubes

Carbon nanotubes (CNTs) are cylindrical structures composed of graphene sheets rolled into tubes. Due to their unique structure, CNTs can carry a wide variety of drugs, including small molecules, peptides, proteins, and nucleic acids. They have been explored as drug delivery vehicles for cancer therapy, as they can penetrate cell membranes and deliver drugs directly to the cytoplasm. CNTs can also be functionalized to target specific cells or tissues.

Advantages:

- High surface area for drug loading
- Ability to penetrate biological barriers
- Potential for targeted delivery through surface modification

Disadvantages:

- Potential toxicity and long-term accumulation in tissues
- Complex functionalization and production processes .

6. Niosomes

Niosomes are non-ionic surfactant-based vesicles that are structurally similar to liposomes. They are composed of non-ionic surfactants and cholesterol, and can encapsulate both hydrophilic and hydrophobic drugs. Niosomes offer enhanced stability over liposomes and are less expensive to produce. They are used in transdermal and targeted drug delivery systems.

Advantages:

- Biocompatible and cost-effective
- Enhanced drug stability compared to liposomes
- Can carry both hydrophilic and hydrophobic drugs

Disadvantages:

- Limited drug-loading capacity
- Potential for aggregation during storage.

7. Micelles

Micelles are self-assembling colloidal particles formed by amphiphilic molecules (molecules with both hydrophilic and hydrophobic ends). The hydrophobic core of the micelle can encapsulate lipophilic drugs, protecting them from degradation and enhancing solubility. Micelles are particularly useful for delivering poorly water-soluble drugs. Polymeric micelles, which are formed from block copolymers, offer additional advantages in terms of stability and drug release control.

Advantages:

- Suitable for solubilizing hydrophobic drugs
- Small size allows for passive targeting via the enhanced permeability and retention (EPR) effect in tumors
- Can be functionalized for active targeting

Disadvantages:

- Limited stability in biological fluids
- Potential for premature drug release before reaching the target.

VIII. ADVANTAGES OF NANOCARRIER SYSTEMS IN DRUG DELIVERY

1. Targeted Drug Delivery: Nanocarriers can be functionalized to target specific tissues or cells, reducing off-target effects and improving drug efficacy. This is especially beneficial in cancer therapy, where targeted delivery can minimize damage to healthy tissues.
2. Controlled Drug Release: Nanocarriers can provide controlled and sustained drug release, which improves therapeutic outcomes by maintaining steady drug levels in the bloodstream for an extended period. This reduces the frequency of dosing and enhances patient compliance.
3. Improved Drug Solubility and Stability: Nanocarriers improve the solubility of poorly water-soluble drugs and protect them from degradation in the biological environment, enhancing their bioavailability.
4. Reduced Side Effects: By delivering drugs specifically to diseased tissues or cells, nanocarriers can reduce the systemic exposure of drugs, thereby minimizing side effects.

IX. CHALLENGES AND DISADVANTAGES OF NANOCARRIER SYSTEMS

1. Complex Formulation Processes: The development of nanocarrier systems is more complex compared to traditional drug formulations. This complexity can lead to higher production costs and longer development times.
2. Potential Toxicity: Some nanocarriers, such as carbon nanotubes and certain polymers, may exhibit toxicity, particularly due to long-term accumulation in tissues or organs. Biodegradability and biocompatibility are major considerations for nanocarrier design.
3. Regulatory and Manufacturing Challenges: Regulatory approval for nanocarrier-based drug delivery systems can be challenging due to concerns about safety and consistency in manufacturing. Additionally, large-scale production of nanocarriers requires specialized equipment and expertise.
4. Stability Issues : Some nanocarriers, such as liposomes, may face stability challenges during storage, leading to drug leakage or aggregation. This can affect the therapeutic efficacy and shelf life of the drug.

X. APPLICATIONS OF NANOCARRIER SYSTEMS IN TRANSDERMAL DRUG DELIVERY

Nanocarrier systems have revolutionized the field of drug delivery by offering improved efficacy, reduced side effects, and enhanced patient compliance. In the realm of transdermal drug delivery, nanocarriers play a pivotal role by enhancing the permeability of drugs through the skin, which serves as a major barrier due to the stratum corneum. Various nanocarrier systems such as liposomes, niosomes, solid lipid nanoparticles (SLNs),

polymeric nanoparticles, and micelles have been extensively researched and developed for transdermal applications. These systems are used to overcome the limitations of traditional transdermal patches by improving drug absorption, prolonging release, and enabling targeted delivery.

Here is a detailed overview of the key applications of nanocarrier systems in transdermal drug delivery.

1. Liposomes in Transdermal Drug Delivery

Liposomes are one of the earliest and most widely used nanocarriers for transdermal drug delivery. Liposomes are spherical vesicles with one or more phospholipid bilayers, which can encapsulate both hydrophilic and lipophilic drugs, making them versatile for transdermal use. Due to their similarity to the lipid content of the skin, liposomes can easily penetrate the stratum corneum and deliver drugs to the deeper layers of the skin or even into the systemic circulation.

• Applications:

- Delivery of Anti-inflammatory Drugs: Liposomal formulations have been employed for the transdermal delivery of nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac. This helps reduce localized inflammation with minimal systemic side effects.
- Vaccine Delivery: Liposomes have been used for the transdermal delivery of vaccines, allowing antigens to reach the immune cells present in the skin. This method provides a non-invasive alternative to injections.
- Dermatological Applications: Liposomes are commonly used to deliver dermatological drugs, such as corticosteroids and retinoids, for treating skin diseases like psoriasis and eczema.

Advantages:

- Improved penetration through the skin
- Biocompatibility and low toxicity
- Controlled and localized drug release

Challenges:

- Stability issues and potential for drug leakage
- Limited shelf life due to lipid oxidation

2. Niosomes for Enhanced Skin Penetration

Niosomes are vesicular systems similar to liposomes, but they are composed of non-ionic surfactants rather than phospholipids. Due to their non-ionic nature, niosomes are more stable than liposomes and can be formulated at a lower cost. They can encapsulate a wide range of drugs and have been studied for transdermal applications due to their ability to enhance skin penetration.

• Applications:

- Hormonal Therapy: Niosomes have been used for the transdermal delivery of hormones like estradiol and testosterone. They provide sustained release, reducing the need for frequent dosing, which improves patient compliance in hormone replacement therapy.
- Transdermal Delivery of Antifungal Agents: Niosomal formulations of antifungal drugs like ketoconazole and miconazole have been developed to treat fungal infections like athlete's foot or fungal nail infections. This localized delivery minimizes systemic exposure and toxicity.

Advantages:

- Enhanced skin permeation due to flexible vesicle structure
- Stable compared to liposomes and easier to store
- Less expensive production process

Challenges:

- Possible aggregation of niosomes during storage
- Lower encapsulation efficiency compared to liposomes

3. Solid Lipid Nanoparticles (SLNs) for Controlled Release

- Solid Lipid Nanoparticles (SLNs) are another promising nanocarrier system used in transdermal drug delivery. SLNs consist of solid lipid cores that encapsulate the drug, offering advantages like good stability,

controlled release, and biocompatibility. They also help to improve the solubility of poorly water-soluble drugs and enhance their penetration through the skin.

• **Applications:**

- Delivery of Anti-aging Compounds: SLNs are commonly used in cosmetics and dermatology for the transdermal delivery of anti-aging agents like coenzyme Q10 (CoQ10) and retinoids. These nanoparticles protect the active ingredients from degradation and provide sustained release to improve efficacy.
- Transdermal Delivery of NSAIDs: SLN-based formulations of drugs like ibuprofen have been explored to provide localized pain relief and reduce systemic side effects associated with oral administration.

Advantages:

- Controlled and sustained drug release over extended periods
- High stability and protection of the drug from degradation
- Biocompatible and safe for topical use

Challenges:

- Limited drug loading capacity
- Potential for drug expulsion during storage

4. Polymeric Nanoparticles for Sustained Transdermal Delivery

Polymeric nanoparticles are composed of biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), which allow for controlled and sustained drug release. These nanoparticles can be engineered to adhere to the skin and slowly release drugs over time, making them ideal for chronic conditions that require long-term treatment.

• **Applications:**

- Transdermal Delivery of Anticancer Drugs: Polymeric nanoparticles have been investigated for the transdermal delivery of chemotherapeutic agents, such as 5-fluorouracil (5-FU), to treat skin cancers. This localized delivery system reduces systemic toxicity and enhances the therapeutic effect at the site of the tumor.
- Transdermal Delivery of Anti-inflammatory Agents: Polymeric nanoparticles have also been explored for delivering anti-inflammatory agents to treat chronic inflammatory conditions like arthritis. The sustained release provided by these nanoparticles reduces the need for frequent dosing and improves patient outcomes.

• Advantages:

- Prolonged and controlled drug release
 - Ability to encapsulate a wide range of drugs
 - Biocompatible and biodegradable polymers
- Challenges:
- Potential for polymer-related toxicity
 - More complex and expensive to formulate compared to lipid-based systems

5. Micelles for Improved Drug Solubility and Delivery

Micelles are self-assembling structures formed by amphiphilic molecules (molecules with both hydrophilic and hydrophobic regions). In transdermal drug delivery, micelles can encapsulate poorly water-soluble drugs within their hydrophobic core, improving the solubility and absorption of these drugs through the skin.

• **Applications:**

- Delivery of Hydrophobic Drugs: Micelles have been extensively used to improve the transdermal delivery of hydrophobic drugs such as paclitaxel and curcumin. These drugs are challenging to deliver through conventional transdermal systems due to their low water solubility, but micelles enhance their penetration and bioavailability.
- Topical Anti-inflammatory Therapy: Micellar systems have been used to deliver anti-inflammatory drugs like indomethacin and diclofenac, providing localized pain relief while minimizing systemic exposure and side effects.

Advantages:

- Enhanced solubility of hydrophobic drugs
- Small size allows for better skin penetration
- Easy to modify for targeted delivery

Challenges:

- Stability issues in biological fluids
- Potential for premature drug release

6. Carbon Nanotubes for Transdermal Drug Delivery

Carbon nanotubes (CNTs) are cylindrical structures made of graphene sheets, and they have gained attention for their ability to deliver a wide variety of drugs transdermally. CNTs can penetrate cell membranes and deliver drugs directly to the cytoplasm, making them useful for both topical and systemic drug delivery.

• Applications:


- Transdermal Gene Therapy: CNTs have been investigated for their ability to deliver genes transdermally for gene therapy applications. This allows for non-invasive genetic treatments for various skin disorders and cancers.
- Delivery of Peptides and Proteins: Due to their ability to penetrate biological barriers, CNTs have been explored for the transdermal delivery of macromolecules like peptides and proteins, which are typically difficult to deliver through the skin.

Advantages:

- High drug loading capacity
- Ability to penetrate biological barriers
- Potential for targeted delivery

Challenges:

- Concerns regarding long-term toxicity and biocompatibility
- Complex functionalization required for safe use



XI. CONCLUSION

Nanocarrier Systems for Transdermal Drug Delivery:

Nanocarrier systems have emerged as a revolutionary approach in transdermal drug delivery, addressing the limitations of traditional delivery methods. By utilizing nanotechnology, these systems significantly enhance

drug penetration through the skin, a formidable barrier to most therapeutic agents. They offer numerous advantages, such as improved bioavailability, controlled release, targeted delivery, and reduced systemic side effects. Various nanocarrier systems—liposomes, niosomes, solid lipid nanoparticles (SLNs), polymeric nanoparticles, micelles, and carbon nanotubes—have demonstrated great potential in delivering a wide range of therapeutic agents transdermally, including small molecules, peptides, proteins, and even genetic material.

• **Key Achievements and Benefits:**

1. **Enhanced Drug Penetration:** Nanocarriers, due to their nanoscale size and adaptable surface properties, can effectively penetrate the skin's outer barrier (the stratum corneum). Systems such as liposomes and niosomes are structurally similar to skin lipids, which facilitates deeper drug penetration.
2. **Improved Drug Solubility:** Nanocarriers like micelles and SLNs are particularly effective in encapsulating hydrophobic drugs, enhancing their solubility and facilitating their transdermal delivery.
3. **Controlled and Sustained Release:** Polymeric nanoparticles and SLNs offer prolonged drug release, which is beneficial for chronic conditions requiring sustained therapeutic levels, thereby reducing dosing frequency and improving patient compliance.
4. **Targeted Delivery:** By modifying nanocarriers with ligands or functional groups, targeted delivery to specific tissues or cells is achievable. This reduces off-target effects and minimizes drug waste, enhancing the efficacy of treatments.
5. **Reduced Side Effects:** Transdermal nanocarriers provide localized drug delivery, reducing systemic exposure and thus minimizing side effects. This is particularly valuable in drugs with narrow therapeutic windows or those that cause adverse systemic reactions when administered orally or intravenously.

Challenges and Future Directions:

Despite these advantages, certain challenges remain. Formulation complexity, stability issues (especially for liposomes and niosomes), potential long-term toxicity (e.g., carbon nanotubes), and the cost of production are significant hurdles that must be addressed. Additionally, the regulatory landscape for nanomedicines is still evolving, and obtaining approval for nanocarrier-based transdermal systems can be more complex compared to traditional formulations.

Future research is expected to focus on overcoming these challenges through advances in nanomaterials, manufacturing processes, and functionalization techniques. Innovations like smart nanocarriers, which can respond to specific stimuli (e.g., pH, temperature), and the integration of nanocarrier systems with wearable technologies may further enhance the efficacy and precision of transdermal drug delivery.

In conclusion, nanocarrier systems hold transformative potential for transdermal drug delivery by improving the effectiveness, safety, and patient experience. With continued research and technological advancements, these systems are poised to play an increasingly important role in personalized medicine, providing safer and more efficient therapeutic options for patients worldwide.

XII. REFERENCES

- [1] Bhatia, S., et al. (2022). Polymeric nanoparticles for transdermal drug delivery: A review. *Journal of Drug Delivery Science and Technology*, 67, 102779.
- [2] Fang, J., et al. (2020). Nanostructured lipid carriers: A versatile nanocarrier system for transdermal drug delivery. *Pharmaceutical Research*, 37(4), 1-12.
- [3] Kumar, S., et al. (2021). Liposomes as a carrier for transdermal delivery of diclofenac: A review. *Current Drug Delivery*, 18(1), 58-70.
- [4] Liu, H., et al. (2021). Microneedle systems for transdermal delivery: A review. *Advanced Drug Delivery Reviews*, 176, 113-130z
- [5] Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: Lessons learned. *Nature Reviews Drug Discovery*, 9(12), 971-978.
- [6] Bhatia, S., et al. (2022). Polymeric nanoparticles for transdermal drug delivery: A review. *Journal of Drug Delivery Science and Technology*, 67, 102779.
- [7] Chakraborty, S., et al. (2019). Nanostructured lipid carriers for drug delivery: A review. *European Journal of Pharmaceutics and Biopharmaceutics*, 145, 263-273.

- [8] Duncan, R. (2019). Nanomedicine opportunities and challenges. *Nature Nanotechnology*, 14(3), 255-257.
- [9] Fang, J., et al. (2020). Nanostructured lipid carriers: A versatile nanocarrier system for transdermal drug delivery. *Pharmaceutical Research*, 37(4), 1-12.
- [10] Gao, Y., et al. (2023). Microneedle systems for drug delivery: Advances and applications. *Advanced Drug Delivery Reviews*, 193, 114-135.
- [11] Jain, K., et al. (2021). Nanocarriers for transdermal drug delivery: A comprehensive review. *Current Pharmaceutical Design*, 27(10), 1349-1367.
- [12] Kumar, S., et al. (2021). Liposomes as a carrier for transdermal delivery of diclofenac: A review. *Current Drug Delivery*, 18(1), 58-70.
- [13] Liu, H., et al. (2021). Microneedle systems for transdermal delivery: A review. *Advanced Drug Delivery Reviews*, 176, 113-130.
- [14] Patel, S. P., et al. (2020). Nanocarrier systems for transdermal delivery of therapeutic agents: A review. *Journal of Drug Delivery Science and Technology*, 57, 101-110.
- [15] Sharma, R., et al. (2021). Solid lipid nanoparticles for transdermal drug delivery: An overview. *Journal of Drug Delivery Science and Technology*, 61, 102-109.
- [16] Tiwari, G., et al. (2020). Polymeric nanoparticles in drug delivery: Current applications and future perspectives. *Current Pharmaceutical Design*, 26(18), 2155-2167.
- [17] Boulant, J. A. (2000). Thermoregulation: A paradigm for the integration of physiology and psychology. *Annual Review of Psychology*, 51, 129-157.
- [18] Bresalier, M., et al. (2003). Pain and the skin: A review of the neurobiology. *Clinical Journal of Pain*, 19(5), 267-273.
- [19] Gallo, R. L., et al. (2002). Antimicrobial peptides: A new family of human antibiotics. *Nature Reviews Drug Discovery*, 1(7), 633-644.
- [20] Holick, M. F. (2004). Vitamin D: A millenium perspective. *Journal of Cellular Biochemistry*, 88(2), 296-307.
- [21] Kumar, S., et al. (2022). Anatomy and physiology of the skin . *Journal of Cutaneous and Aesthetic Surgery*, 15(2), 102-109.
- [22] Madison, K. C. (2003). Barrier Function of the Skin: La Raison D'Être of the Epidermis. *Journal of Investigative Dermatology*, 121(2), 231-241.
- [23] Proksch, E., et al. (2008). Skin barrier function: Biochemical and physical aspects. *Journal of Dermatological Science*, 50(1), 60-65.
- [24] Rittie, L., & Fisher, G. J. (2002). Fibroblast and keratinocyte senescence: Implications for skin aging and repair. *Journal of Investigative Dermatology Symposium Proceedings*, 7(1), 13-18.
- [25] Choi, S. J., et al. (2021). Transdermal drug delivery: Mechanisms, methods, and recent advances. *Journal of Controlled Release*, 329, 116-136.
- [26] Khan, A. A., et al. (2020). Chemical penetration enhancers in transdermal drug delivery: A review. *Journal of Pharmaceutical Sciences*, 109(6), 1791-1804.
- [27] Liu, H., et al. (2021). Microneedle systems for transdermal delivery: Advances and applications. *Advanced Drug Delivery Reviews*, 176, 113-130.
- [28] Mitragotri, S., et al. (2019). Transdermal drug delivery: Innovations and applications. *Nature Reviews Drug Discovery*, 18(5), 273-290.
- [29] Mok, S. Y., et al. (2019). Microneedle-mediated transdermal delivery: Challenges and solutions. *Pharmaceutical Research*, 36(10), 150.
- [30] Yin, H., et al. (2016). Nanoparticle-based drug delivery systems for treating bacterial infections. *Nanomedicine*, 15(5), 493-511.
- [31] Zhou, Y., et al. (2021). Transdermal drug delivery systems: Mechanisms, recent advances, and future perspectives. *Therapeutic Delivery*, 12(6), 349-366.
- [32] Guy, R.H. "Current status and future prospects of transdermal drug delivery." *Pharmaceutical Research* (1996).

- [33] Prausnitz, M.R., Mitragotri, S., & Langer, R. "Current status and future potential of transdermal drug delivery." *Nature Reviews Drug Discovery* (2004).
- [34] Barry, B.W. "Mode of action of penetration enhancers in human skin." *Journal of Controlled Release* (1987).
- [35] Bouwstra, J.A., & Honeywell-Nguyen, P.L. "Skin structure and mode of action of vesicles." *Advanced Drug Delivery Reviews* (2002).
- [36] Flynn, G.L. "Physicochemical determinants of skin absorption." *Principles of Route-to-Route Extrapolation for Risk Assessment* (1990).
- [37] Elias, P.M. "Stratum corneum barrier function." *Journal of Investigative Dermatology* (1983).
- [38] Zhai, H., & Maibach, H.I. "Effects of skin occlusion on percutaneous absorption: An overview." *Skin Pharmacology* (2001).
- [39] Trommer, H., & Neubert, R.H. "Overcoming the stratum corneum: the modulation of skin penetration." *Skin Pharmacology and Physiology* (2006).
- [40] Monteiro-Riviere, N.A. "Penetration of industrial chemicals through the skin: a review of the literature." *Journal of Toxicology and Environmental Health* (1999).
- [41] Benson, H.A.E. "Transdermal drug delivery: penetration enhancement techniques." *Current Drug Delivery* (2005).
- [42] Patel, R.B., Naik, S., Patel, M.R., & Patel, J.K. "Transdermal drug delivery system: Review." *International Journal of Pharmaceutical Research* (2011).
- [43] Williams, A.C., & Barry, B.W. "Penetration enhancers." *Advanced Drug Delivery Reviews* (2004).
- [44] Brown, M.B., Martin, G.P., Jones, S.A., & Akomeah, F.K. "Dermal and transdermal drug delivery systems: current and future prospects." *Drug Delivery* (2006).
- [45] Pathak, P. "Role of formulation pH in topical delivery." *Journal of Drug Delivery* (2013).
- [46] Karande, P., & Mitragotri, S. "Enhancement of transdermal drug delivery via synergistic action of chemicals." *Biochimica et Biophysica Acta* (2009).
- [47] Schaefer, H., & Redelmeier, T.E. "Skin Barrier: Principles of Percutaneous Absorption." *Karger* (1996)
- [48] Guy, R.H. "Current status and future prospects of transdermal drug delivery." *Pharmaceutical Research* (1996).
- [49] Prausnitz, M.R., Mitragotri, S., & Langer, R. "Current status and future potential of transdermal drug delivery." *Nature Reviews Drug Discovery* (2004).
- [50] Benson, H.A.E. "Transdermal drug delivery: penetration enhancement techniques." *Current Drug Delivery* (2005).
- [51] Flynn, G.L. "Physicochemical determinants of skin absorption." *Principles of Route-to-Route Extrapolation for Risk Assessment* (1990).
- [52] Monteiro-Riviere, N.A. "Penetration of industrial chemicals through the skin: a review of the literature." *Journal of Toxicology and Environmental Health* (1999).
- [53] Trommer, H., & Neubert, R.H. "Overcoming the stratum corneum: the modulation of skin penetration." *Skin Pharmacology and Physiology* (2006).
- [54] Karande, P., & Mitragotri, S. "Enhancement of transdermal drug delivery via synergistic action of chemicals." *Biochimica et Biophysica Acta* (2009).
- [55] Brown, M.B., Martin, G.P., Jones, S.A., & Akomeah, F.K. "Dermal and transdermal drug delivery systems: current and future prospects." *Drug Delivery* (2006).
- [56] Zhai, H., & Maibach, H.I. "Effects of skin occlusion on percutaneous absorption: An overview." *Skin Pharmacology* (2001).
- [57] Barry, B.W. "Mode of action of penetration enhancers in human skin." *Journal of Controlled Release* (1987).
- [58] Pathak, P. "Role of formulation pH in topical delivery." *Journal of Drug Delivery* (2013).
- [59] Elias, P.M. "Stratum corneum barrier function." *Journal of Investigative Dermatology* (1983).
- [60] Bouwstra, J.A., & Honeywell-Nguyen, P.L. "Skin structure and mode of action of vesicles." *Advanced Drug Delivery Reviews* (2002).
- [61] Schaefer, H., & Redelmeier, T.E. "Skin Barrier: Principles of Percutaneous Absorption." *Karger* (1996).

-
- [62] Williams, A.C., & Barry, B.W. "Penetration enhancers." *Advanced Drug Delivery Reviews* (2004).
- [63] Patel, R.B., Naik, S., Patel, M.R., & Patel, J.K. "Transdermal drug delivery system: Review." *International Journal of Pharmaceutical Research* (2011).
- [64] Monteiro-Riviere, N.A., & Inman, A.O. "Adhesive-related contact dermatitis associated with transdermal therapeutic systems." *Journal of Clinical Dermatology* (2001).
- [65] Torchilin, V.P. "Recent advances with liposomes as pharmaceutical carriers." *Nature Reviews Drug Discovery* (2005).
- [66] Sahoo, S.K., & Labhasetwar, V. "Nanotech approaches to drug delivery and imaging." *Drug Discovery Today* (2003).
- [67] Panyam, J., & Labhasetwar, V. "Biodegradable nanoparticles for drug and gene delivery to cells and tissue." *Advanced Drug Delivery Reviews* (2003).
- [68] Liu, Z., Tabakman, S.M., Chen, Z., & Dai, H. "Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging, and drug delivery." *Nano Research* (2009).
- [69] Brigger, I., Dubernet, C., & Couvreur, P. "Nanoparticles in cancer therapy and diagnosis." *Advanced Drug Delivery Reviews* (2002).
- [70] Koo, H., Huh, M.S., Ryu, J.H., et al. "Nanoprobes for biomedical imaging in living systems." *Nano Today* (2011).
- [71] Choi, K.Y., Liu, G., Lee, S., & Chen, X. "Theranostic nanoplatfoms for simultaneous cancer imaging and therapy: current approaches and future perspectives." *Nanoscale* (2012).
- [72] Agrahari, V., Hiremath Bouwstra, J.A., & Honeywell-Nguyen, P.L. "Skin structure and mode of action of vesicles in dermal and transdermal drug delivery." *Advanced Drug Delivery Reviews* (2002).
- [73] Williams, A.C., & Barry, B.W. "Penetration enhancers." *Advanced Drug Delivery Reviews* (2004).
- [74] Mishra, D., Dubey, V., Asthana, A., & Jain, N.K. "Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: Propranolol hydrochloride." *Journal of Pharmacy and Pharmacology* (2006).
- [75] Souto, E.B., & Müller, R.H. "Solid lipid nanoparticles for advanced drug delivery."